Medidata
Medidata Solutions, Inc., headquartered in the United States, is a leading player in the life sciences industry, specialising in cloud-based solutions for clinical trials. Founded in 1999, the company has achieved significant milestones, including the development of innovative technologies that streamline the drug development process. With a strong presence in North America, Europe, and Asia, Medidata offers a comprehensive suite of products and services, including data management, analytics, and patient engagement tools. Their unique platform integrates advanced analytics and artificial intelligence, enabling biopharmaceutical companies to enhance decision-making and improve trial outcomes. Recognised for its market leadership, Medidata has been instrumental in transforming clinical research, supporting over 25,000 trials and 5 million patients globally. The company’s commitment to innovation and excellence positions it as a trusted partner in the evolving landscape of clinical development.
DitchCarbon Score
How does Medidata's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medidata's score of 56 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medidata's reported carbon emissions
In 2023, Medidata reported total carbon emissions of approximately 908,000 kg CO2e, comprising 52,000 kg CO2e from Scope 1, 22,000 kg CO2e from Scope 2, and about 836,000 kg CO2e from Scope 3 emissions. This data reflects a comprehensive approach to emissions reporting, including all relevant scopes. Medidata has set ambitious climate commitments, aiming for a 35% reduction in greenhouse gas emissions across Scopes 1 and 2 by 2027, using 2019 as the baseline year. Additionally, the company is working towards achieving carbon neutrality by 2040, which will involve offsetting residual emissions, excluding those from the use of sold solutions. The company is also transitioning to a fossil fuel-free fleet of company cars, which is expected to further reduce greenhouse gas emissions and enhance air quality. This initiative is part of their near-term strategy, with a focus on both Scope 1 and Scope 2 emissions. It is important to note that Medidata's emissions data is cascaded from its parent company, Dassault Systèmes SE, reflecting a corporate family relationship. This ensures alignment with broader sustainability goals set by the parent organisation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | 000,000 | 000,000 | 00,000 |
| Scope 2 | 1,831,000 | 0,000,000 | 0,000,000 | 00,000 |
| Scope 3 | 6,330,040 | 00,000,000 | 00,000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medidata is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
